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Summary
 
The induction of T cell anergy in vivo is thought to result from antigen recognition in the ab-
sence of co-stimulation and inflammation, and is associated with a block in T cell proliferation
and Th1 differentiation. Here we have examined the role of interleukin (IL)-12, a potent in-
ducer of Th1 responses, in regulating this process. T cell tolerance was induced by the admin-
istration of protein antigen without adjuvant in normal mice, and in recipients of adoptively
transferred T cells from T cell receptor transgenic mice. The administration of IL-12 at the
time of tolerance induction stimulates Th1 differentiation, but does not promote antigen-spe-
cific T cell proliferation. Conversely, inhibiting CTLA-4 engagement during anergy induction
reverses the block in T cell proliferation, but does not promote full Th1 differentiation. T cells
exposed to tolerogenic antigen in the presence of both IL-12 and anti–CTLA-4 antibody are
not anergized, and behave identically to T cells which have encountered immunogenic anti-
gen. These results suggest that two processes contribute to the induction of anergy in vivo;
CTLA-4 engagement, which leads to a block in the ability of T cells to proliferate to antigen,
and the absence of a prototypic inflammatory cytokine, IL-12, which prevents the differentia-
tion of T cells into Th1 effector cells. The combination of IL-12 and anti–CTLA-4 antibody is
sufficient to convert a normally tolerogenic stimulus to an immunogenic one.
 
C
 
lonal anergy is an important mechanism of peripheral
T cell tolerance (1, 2). The development of anergy
was first analyzed in cloned lines of mouse Th1 cells. These
studies have led to the widely accepted view that anergy is
induced when antigen is recognized in the absence of sec-
ond signals (3–5), the best defined of which are costimula-
tors of the B7 family (6). Thus classical studies, showing
that antigens administered with strong adjuvants elicit T
cell responses and antigens without adjuvants induce toler-
ance, are now interpreted to suggest that an important
function of adjuvants is to enhance the expression of the
costimulators that determine whether antigen recognition
will lead to activation or anergy (3). Based on these ideas,
many attempts have been made to prevent immune reac-
tions, e.g., against organ allografts, and to induce tolerance
by blocking B7 molecules in vivo (7–10). Conversely, the
ectopic expression of B7 proteins in tissues results in an in-
creased predisposition to tissue-specific autoimmune in-
jury, presumably by breaking T cell tolerance to self anti-
gens in the tissues (11–14).
Two sets of findings suggest that costimulators alone may
not dictate the choice between T cell activation and toler-
ance. First, expression of B7-1 as a transgene in tissues does
not, by itself, lead to autoimmune disease. In most of these
studies, an additional local stimulus, such as the proinflam-
matory cytokine TNF-
 
a
 
, has to be provided (13). Second,
we have recently shown that completely blocking costimu-
lation during exposure to antigen leads to a state of clonal
ignorance and not to anergy in vivo (15). In fact, anergy
develops when antigen-specific T cells use the inhibitory
receptor for B7 molecules, CTLA-4, to interact with co-
stimulators at the time of antigen recognition. These results
provide an explanation for the severe autoimmune disease
that develops in mice in which CTLA-4 is deleted by tar-
geted gene disruption (16, 17). Thus, the choice between
T cell activation versus anergy may be determined partly by
whether CD28 or CTLA-4 engages B7 molecules on
APCs (18). Although the mechanisms that influence this
choice are not yet defined, the findings do suggest that simply
the absence of costimulation may not be the mechanism of
T cell anergy in vivo.
It is well known that adjuvants induce the production of
numerous cytokines from APCs. One of these cytokines,
IL-12, is a potent, and obligatory, inducer of Th1 differen-
tiation (19). Since T cell anergy preferentially affects Th1
cells (3, 20–22), we postulated that a deficiency of local IL-
12 production may play an important role in the induction
of anergy. We have tested this hypothesis in two experi-
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mental models of T cell anergy induced in vivo, i.e., nor-
mal mice and recipients of T cells from TCR transgenic
mice treated with high doses of antigen in the absence of
adjuvant. We show that in both models of anergy, IL-12
by itself promotes Th1 differentiation, but not T cell prolif-
eration or expansion, in response to tolerogenic antigen.
Blocking CTLA-4 during anergy induction overcomes the
block in T cell expansion, but does not lead to full Th1 dif-
ferentiation. Exposure to tolerogenic antigen in the pres-
ence of both IL-12 and an anti–CTLA-4 antibody prevents
the induction of anergy, and induces a full T cell response.
Thus, anergy induction in vivo involves both a block in
Th1 differentiation and in T cell proliferation. These dif-
ferent aspects of T cell anergy are regulated by IL-12 and
CTLA-4, respectively. Local inflammation also prevents
the induction of T cell anergy, presumably by stimulating
IL-12 secretion and changing the expression and recogni-
tion of costimulators. Our results support the potential im-
portance of IL-12 in breaking T cell tolerance, e.g., in au-
toimmune diseases, and conversely, the potential of IL-12
antagonists in inducing tolerance, e.g., to allografts.
 
Materials and Methods
 
Mice.
 
BALB/c mice, 6–8 wk old, were purchased from the
Jackson Laboratory (Bar Harbor, ME). Transgenic mice express-
ing the DO.11.10 TCR (hereafter called DO.11) specific for the
chicken OVA peptide, OVA
 
323–339
 
, in association with I-A
 
d
 
 were
obtained from Dr. D. Loh (Hoffmann-La Roche, Tokyo, Japan).
The mice were bred in our pathogen- and viral antibody–free fa-
cility in accordance with the guidelines of the Committee on An-
imals of the Harvard Medical School (Cambridge, MA) and those
prepared by the Committee on Care and Use of Laboratory Ani-
mals of the Institute of Laboratory Resources, National Research
Council (Washington, DC). The mice were typed for the DO.11
by staining peripheral blood cells with antibodies against CD4
and V
 
b
 
8.
 
Adoptive Transfers and In Vivo Tolerance Induction.
 
To induce
tolerance in normal BALB/c mice, animals were treated with
0.3–1 mg i.p. of OVA or PBS. 7–10 d later, mice were immu-
nized with 100 
 
m
 
g OVA in CFA (Difco, Detroit, MI) and s.c.
Draining lymph nodes were harvested 7 d later and assayed as de-
scribed below. To induce tolerance in TCR transgenic T cells,
we used the protocol described by Kearney et al. (23). Lymph
node and spleen cells pooled from DO.11 transgenic mice were
prepared as previously described (15) and injected intravenously
into unirradiated syngeneic BALB/c recipients, such that each re-
ceived 5 
 
3
 
 10
 
6
 
 KJ-126
 
1
 
 CD4
 
1
 
 T cells. The recipients were ei-
ther not immunized (naive), or 2 d after cell transfer were treated
subcutaneously in the footpad with 50 
 
m
 
g of the OVA
 
323–339
 
 pep-
tide emulsified in IFA (immunized) or intravenously with 300 
 
m
 
g
of the peptide in PBS (tolerized). The peripheral lymph nodes
(submandibular, axillary, brachial, inguinal, and popliteal) were
harvested 3 d after treatment in all the groups except for the im-
munized recipients, from which only the draining lymph nodes
(inguinal and popliteal) were harvested. For in vivo challenge ex-
periments, mice treated as described above were immunized sub-
cutaneously in the footpad with 50 
 
m
 
g of the peptide emulsified
in IFA 10 d after the initial treatment, and the draining lymph
nodes (inguinal and popliteal) were harvested 3 d later. To study
the effects of cytokines and costimulation on the induction of tol-
erance, mice were treated either with 0.3–3 
 
m
 
g of murine IL-12 (gift
from Dr. S. Wolf, Genetics Institute, Andover, MA) or 100 
 
m
 
g of
anti–CTLA-4 antibody (reference 18; gift from Dr. J. Bluestone,
University of Chicago, Chicago, IL) on days 
 
2
 
1, 0, and 
 
1
 
1 of
the initial antigen exposure. To study the effects of local inflam-
mation on the induction of tolerance, tolerized mice were given
PBS emulsified in CFA subcutaneously in the footpad on day 0.
After the harvest, the lymph node cells from each group were
stained with CyC-labeled anti-CD4 mAb (PharMingen, San Di-
ego, CA) and biotinylated KJ-126 clonotypic antibody specific
for the DO.11 followed by streptavidin-FITC for FACS
 
Ò
 
 analy-
sis. Analyses were performed on a FACScan
 
Ò
 
 flow cytometer.
 
In Vitro Proliferation and Cytokine Assays.
 
Harvested cells were
assayed as previously described (15). In brief, 5 
 
3
 
 10
 
5
 
 lymph node
cells from each of the groups were cultured in 0.2 ml of RPMI
1640 supplemented with 1 mM 
 
l
 
-glutamine, penicillin, strepto-
mycin, nonessential amino acids, sodium pyruvate, Hepes (all
from Life Technologies, Grand Island, NY), 5 
 
3
 
 10
 
2
 
5
 
 M 2-ME,
and 10% fetal bovine serum (Sigma Chemical Co., St. Louis,
MO). Cells were restimulated with 0–1 
 
m
 
g/ml of OVA
 
323–339
 
.
After 48 h, cultures were pulsed for 6 h with 1 
 
m
 
Ci [
 
3
 
H]TdR
(New England Nuclear, Boston, MA), and incorporated radioac-
tivity was measured in a Betaplate scintillation counter (LBK
Pharmacia, Piscataway, NJ). To determine cytokine production,
2 
 
3
 
 10
 
6
 
 lymphocytes were cultured in 1 ml of medium in the
presence of 0, 0.1, or 1 
 
m
 
g/ml of OVA
 
323–339
 
. Supernatants were
collected after 24, 48, and 72 h, and levels of IL-2, IL-4, and
IFN-
 
g
 
 were assayed by ELISA as described previously (15). In
some experiments, CD4
 
1
 
 T cells were purified from the lymph
nodes of experimental mice using CD4
 
1
 
 Dynalbeads
 
Ò
 
 (Dynal
A.S., Oslo, Norway), and cultured with mitomycin C–treated
BALB/c splenocytes as APCs. Typically, T cell preparations were
 
.
 
98% CD4
 
1
 
 as determined by staining and flow cytometry.
 
Intracellular Staining for IFN-
 
g
 
.
 
5 
 
3
 
 10
 
5
 
 lymph node cells
were restimulated with 1 
 
m
 
g/ml OVA
 
323–339
 
 for 24 h. During the
last 6 h, 10 
 
m
 
g/ml brefeldin A (Sigma Chemical Co.) was added
to cultures. The lymph node cells were then washed in PBS/1%
BSA containing 10 
 
m
 
g/ml brefeldin A, stained with antibodies to
CD4 and the DO.11 (with the monoclonal antibody KJ-126; ref-
erence 24), and fixed overnight with 4% paraformaldehyde (Sigma
Chemical Co.). The fixed cells were permeabilized by incubation
in PBS with 1% BSA and 2% saponin (Sigma Chemical Co.) at
room temperature for 10 min. A phycoerythrin-conjugated anti–
IFN-
 
g
 
 antibody (PharMingen), diluted to 20 
 
m
 
g/ml in PBS with
1% BSA and 2% saponin was then added, and the cells were incu-
bated for a further 30 min. Finally, the cells were washed once
with PBS with 1% BSA and 2% saponin and once with PBS with
1% BSA, and analyzed on a FACScan
 
Ò
 
 flow cytometer.
 
Results
 
IL-12 Promotes Th1 Differentiation in Response to Tolerogen-
ic Antigen, but Does not Rescue T Cell Proliferation.
 
T cell re-
sponses to antigen are induced by administering a foreign
antigen subcutaneously with an adjuvant. In contrast, T cells
are rendered unresponsive when high doses of antigen are
given systemically in the absence of adjuvant (20–23). A
vigorous response to OVA can be detected in the periph-
eral lymph node cells of BALB/c mice immunized with
 
1
 
Abbreviations used in this paper:
 
 DO.11, DO.11.10 TCR. 
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OVA in CFA subcutaneously (Fig. 1). If these mice are
pretreated with 1 mg of OVA in saline i.v., they fail to
generate Th1 responses when they are subsequently immu-
nized with antigen in CFA (Fig. 1). Noticeably, Th2 re-
sponses to OVA are not abrogated in tolerized mice. The
observation that tolerance is associated with a selective Th1
block led us to examine whether anergy induction was a
result of antigen recognition in the absence of the major
Th1-inducing cytokine, IL-12 (19). Moreover, the pro-
duction of IL-12 is enhanced by inflammatory stimuli, and
it is likely to be poorly expressed under the conditions
where anergy is induced. When mice are tolerized and
given three daily injections of recombinant IL-12 (1 
 
m
 
g
i.p.), the T cells secrete IFN-
 
g
 
 after a challenge with anti-
gen in adjuvant (Fig. 1). However, IL-12 is not able to pre-
vent the proliferative block associated with anergy.
The limitation of studying T cell responses to immuno-
genic and tolerogenic antigen in normal mice is that the
fate of antigen-specific T cells can not be followed. There-
fore, it is difficult to determine if the inability of T cells to
respond to antigen is due to the deletion, migration, or
functional inactivation of antigen-specific T cells. To study
the regulation of T cell anergy by IL-12 in antigen-specific
T cells, we used the method described by Kearney et al.
(23), in which small numbers of DO.11 transgenic T cells
(specific for OVA
 
323–339
 
1
 
 I–A
 
d
 
) are adoptively transferred
into syngeneic BALB/c mice and exposed to antigen in
immunogenic or tolerogenic form. Approximately 1–2% of
the peripheral lymph node cells in these adoptive transfer
recipients are OVA-specific DO.11 T cells, and these can
be readily followed using a clonotypic mAb (KJ-126; refer-
ence 24). DO.11 T cells can be tolerized in vivo by treat-
ing adoptive transfer recipients with high doses of aqueous
OVA
 
323–339
 
 peptide intraveneously (see below, and references
15 and 23).
Two important features of the adoptive transfer system
are that responses of naive T cells can be measured, and that it
Figure 1. IL-12 promotes Th1 differentiation in response to tolero-
genic antigen in vivo. BALB/c mice were pretreated on day 0 with saline
(immunized) or 1 mg of OVA i.v. (tolerized), with or without daily treat-
ments (days 21, 0, 11) of 1 mg of IL-12 (tolerized 1 IL-12). All mice
were immunized with OVA emulsified in CFA in the footpad on day 10.
The popliteal and inguinal lymph nodes were harvested 7 d later, and
lymph node cells were restimulated in vitro with OVA. Proliferative re-
sponses (A) were assessed after 72 h by measuring [3H]thymidine incorpo-
ration, and cytokine secretion (B) was assayed by ELISA. Results are from
one representative experiment of three. The error bars represent standard
deviations calculated from duplicate wells.
 
Table 1.
 
Effects of Increasing Doses of IL-12 on T Cell Responses 
In Vivo
 
IL-12 Naive Immunized Tolerized
T cell expansion in vivo
No. KJ-126
 
1
 
 T cells (
 
3
 
 10
 
2
 
4
 
) per lymph node
 
m
 
g/d
 
0 1.7 
 
6
 
 0.8 31 
 
6
 
 6.5 16.9 
 
6
 
 5.3
0.3 ND ND 17.3 
 
6
 
 2.4
1 4.1 
 
6
 
 1.1 44.5 
 
6
 
 9.1 22.3 
 
6
 
 8.6
3 6.6 
 
6
 
 1.8 ND 63.1 
 
6
 
 18.2
In vitro proliferation after restimulation with peptide
Proliferation (CPM/KJ-126
 
1
 
 cell) after 3 d of
restimulation
 
m
 
g/d
 
0 12.4 
 
6
 
 2.4 22.8 
 
6
 
 1.0 10.3 
 
6
 
 0.9
0.3 ND ND 8.9 
 
6
 
 0.6
1 12.4 
 
6
 
 1.3 30.5 
 
6
 
 2.4 8.3 
 
6
 
 0.1
3 10.5 
 
6
 
 2.6 ND 12.9 
 
6
 
 3.2
In vitro IFN-
 
g
 
 production following restimulation with peptide
IFN-
 
g
 
 (U/ml) production after 3 d of restimulation
 
m
 
g/d
 
0 0 169 
 
6
 
 9 0
0.3 ND ND 52 
 
6
 
 13
1 24 
 
6
 
 4 212 
 
6
 
 49 157 
 
6
 
 41
3 78 
 
6
 
 3 ND 199 
 
6
 
 18
Peripheral lymph nodes (axillary, brachial, inguinal, and popliteal for
D3 naive and tolerized mice, inguinal and popliteal only for D3 immu-
nized) were harvested from adoptive transfer recipients which were
treated as described in the text. The percentage of KJ-126
 
1
 
 CD4
 
1
 
 cells
present was determined by flow cytometry. To obtain the total num-
bers of KJ-126
 
1
 
 cells present per lymph node, the percent of KJ-126
 
1
 
cells in lymph nodes was multiplied by the total number of cells recov-
ered in each group and divided by the number of lymph nodes har-
vested. In vitro proliferation and IFN-
 
g
 
 production was assessed by re-
stimulating lymph node cells with 1 
 
m
 
g/ml OVA 
 
323–339
 
 peptide for 3 d.
Every treatment group consisted of two to three mice. The numbers
shown are the averages of two to four experiments. 
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is possible to detect changes in functional response patterns
within 3 d of antigen exposure. At this time, one can
readily distinguish naive, activated (immunized), and toler-
ized T cells (Fig. 2). Naive cells produce IL-2 with a peak
at 
 
zday 3 of in vitro stimulation with antigen, proliferate
weakly, and do not produce IFN-g. T cells from immu-
nized mice produce IL-2 rapidly, show strong proliferation,
and secrete IFN-g. (The decline in supernatant IL-2 levels
with increasing duration of culture may be due to absorp-
tion of secreted IL-2 by the proliferating T cells.) Tolerized
cells do not proliferate or secrete IL-2 or IFN-g. Similar to
the results obtained with normal BALB/c mice (Fig. 1), ad-
ministration of IL-12 (1 mg/d) at the time of tolerance in-
duction markedly enhances IFN-g secretion, but has no ef-
fect on IL-2 production and proliferation in this adoptive
transfer tolerance system (Fig. 2).
To exclude a contribution of differential T cell expan-
sion in vivo on responses to antigen restimulation, CD41 T
cells were purified from the lymph nodes of naive, immu-
nized, and tolerized mice that either had been treated or
had not been treated with IL-12. By determining the per-
centage of KJ-1261 cells present in these purified CD41 T
cell populations, we were able to set up restimulation assays
with the same number of DO.11 T cells from each group
of mice (4,000–5,000 KJ-1261 T cells/well for prolifera-
tion assays and 20,000–25,000 KJ-1261 T cells/well for cy-
Figure 2. IL-12 promotes early Th1 differentiation, but not T cell proliferation, in antigen-specific T cells exposed to tolerogenic antigen. BALB/c re-
cipients of DO.11 T cells were left untreated (A); immunized with OVA323–339 peptide in IFA in the footpad on day 0 (B); tolerized with OVA323–339
peptide intravenously on day 0 (C); or tolerized and treated daily (days 21, 0, 11) with 1 mg of IL-12 (D). The submandibular, axillary, brachial,
popliteal, and inguinal lymph nodes (only popliteal and inguinal lymph nodes in B) were harvested 3 d later. Lymph node cells were restimulated in vitro
with OVA323–339 peptide. Proliferative responses were assessed after 72 h by measuring [3H]-thymidine incorporation, and are corrected for the numbers
of KJ-1261 CD41 cells per well. Cytokine secretion was assayed daily by ELISA. Results are from one representative experiment of three. The error bars
represent standard deviations calculated from duplicate wells.1123 Van Parijs et al.
tokine assays), and use syngeneic spleen cells from untreated
mice as APCs. As shown in Fig. 3, IFN-g is detected in
cultures of purified T cells from tolerized mice given IL-12,
demonstrating that they are able to secrete this cytokine
when restimulated with antigen in vitro. These T cells do
not produce IL-2 or proliferate when restimulated with
OVA323–339 peptide, confirming that IL-12 does not pre-
vent the block in T cell proliferation associated with anergy
induction. The results obtained in this set of experiments,
using equivalent numbers of purified antigen-specific T
cells from different experimental groups of mice, were
identical to those obtained with bulk lymph node cultures
(Fig. 2). We therefore used unfractionated lymph node
cells in all subsequent experiments.
Since IL-12 is known to stimulate both T cells and NK
cells to produce IFN-g, an important question is, what cells
produce IFN-g in mice given tolerogenic antigen 1 IL-12.
When lymph node cells from tolerized mice treated with
IL-12 are restimulated in vitro, the secretion of IFN-g is
antigen dose–dependent, suggesting that OVA323–339-spe-
cific DO.11 T cells are the source of this cytokine. The
production of IFN-g can be directly visualized by intracel-
lular staining and flow cytometry. As shown in Fig. 4, anti-
gen-specific T cells exposed in vivo to immunogenic anti-
gen or tolerogenic antigen and IL-12 synthesize detectable
levels of IFN-g when restimulated with antigen in culture.
In contrast, naive or tolerized T cells do not make IFN-g,
and under these conditions KJ-1262 cells also do not syn-
thesize IFN-g. Therefore, in lymph node cells stimulated
with antigen in vitro, the major source of IFN-g is the an-
tigen-specific T cells.
Finally, we have also examined the effects of different
doses of IL-12 on T cell expansion and functional re-
sponses. The injection of tolerogenic antigen (aqueous
peptide intravenously) results in a significant expansion of
antigen-specific T cells, although this is not as great as the
expansion seen in draining lymph nodes after priming with
peptide in adjuvant (Table 1). Administration of up to 1
mg/d of IL-12 together with tolerogenic antigen has a
small effect on T cell numbers. This effect is more pro-
Figure 3. Purified, anergic antigen-specific T cells treated with IL-12 in vivo produce IFN-g, but do not proliferate. BALB/c recipients of DO.11 T
cells were treated as in Fig. 2. CD41 T cells were purified from lymph node cells. An aliquot of the purified CD41 T cells was stained with antibodies to
CD4 and the DO.11 (KJ-126) to determine the percentage of KJ-1261 T cells present. Equal numbers of antigen-specific T cells were restimulated in
vitro with OVA323–339 peptide and syngeneic spleen cells from BALB/c mice as APCs. Proliferative responses of 5,000 DO.11 T cells/well, and cytokine
secretion from 25,000 DO.11 T cells/well, were assayed as in Fig. 2. Results are from one representative experiment of two. The error bars represent
standard deviations calculated from duplicate wells.1124 Interleukin 12 and CTLA-4 in T Cell Anergy
nounced at higher concentrations of IL-12 (Table 1), and is
probably due to an antigen-independent polyclonal stimu-
lation induced by IL-12 (24a). If adoptive transfer recipi-
ents are treated with IL-12 alone, without antigen, the
numbers of lymph node cells recovered, as well as the
numbers of KJ-1261 cells, increase about two- to threefold
(Table 1). Lower doses of IL-12 do not induce this poly-
clonal response, but at these doses the Th1 response is also
much less. Interestingly, despite the T cell expansion seen
with tolerogenic antigen, and even more with tolerogenic
antigen 1 IL-12, the cells do not proliferate upon in vitro
restimulation. This suggests that IL-12 may augment the
abortive T cell response to tolerogenic antigen, but is not
able to prevent the proliferative block associated with an-
ergy.
The Combination of IL-12 and Anti-CTLA-4 Antibody Pre-
vents the Induction of Anergy In Vivo. We have recently
shown that tolerance induction in vivo is due to an active
inhibition that requires the recognition of B7 molecules by
the inhibitory T cell receptor for B7, CTLA-4 (15). This
raises the possibility that blocking CTLA-4 may enable T
cells to proliferate in response to tolerogenic antigen and,
Figure 4. Intracellular stain-
ing for IFN-g in immunized and
tolerized DO.11 T cells. BALB/c
recipients of DO.11 T cells were
treated as in Fig. 2. CD41 T cells
were purified from lymph node
cells. Lymph node cells were re-
stimulated in vitro with 1 mg/ml
OVA323–339 peptide for 24 h,
stained for expression of CD4, the
DO.11, and intracellular IFN-g
as described in Materials and
Methods, and analyzed by flow
cytometry. The dot plots show
expression of KJ-126 and IFN-g
in CD41 T cells, and the histo-
grams show the expression of
IFN-g in KJ-1261 CD41 T cells
(continuous black lines). Control
stains are represented by the dis-
continuous grey lines.1125 Van Parijs et al.
together with IL-12, may convert a normally tolerogenic
stimulus to an immunogenic one. To test this, DO.11
transfer recipients were tolerized by injection of aqueous
peptide antigen, and treated with anti–CTLA-4 mAb, IL-
12, or both. As shown in Fig. 5, in mice given tolerogenic
antigen, anti–CTLA-4 mAb significantly enhances IL-2
production and antigen-specific T cell proliferation, IL-12
alone promotes IFN-g production, and the two together
stimulate responses to tolerogenic antigen that are compa-
rable to those induced in draining lymph node cells after
immunization with antigen in adjuvant. Furthermore,
blocking CTLA-4 enables T cells to expand in vivo after
administration of tolerogenic antigen (Table 2).
The expression of IL-12 and costimulatory molecules by
tissue APCs is enhanced by adjuvants and various microbial
products (6, 19). We therefore asked if local inflammation
provided by a strong adjuvant would also prevent the in-
duction of T cell tolerance. To do this, DO.11 transfer re-
cipients were given tolerogenic antigen (aqueous peptide
intravenously) and treated with CFA, a potent adjuvant,
subcutaneously. The expansion and functional responses of
T cells were assayed in peripheral lymph nodes which did
or did not drain the site of inflammation. As shown in Fig.
6, anergy is induced in lymph nodes away from the site of
CFA injection. However, T cells in lymph nodes which
are near the sites of inflammation are not anergized, and re-
spond as if they had encountered immunogenic antigen.
Furthermore, the expansion of T cells in response to
tolerogenic antigen is significantly enhanced in the lymph
nodes near the source of inflammation. In two experi-
ments, the numbers of KJ-1261 cells (3 1024) in lymph
nodes of different mice were: naive, 2.3 6 0.6; immunized
(draining nodes only), 27.1 6 4.8; tolerized, 17.1 6 5.9;
tolerized 1 local CFA (draining nodes only), 45.6 6 12.3;
and tolerized 1 distant CFA (nondraining nodes), 15.8 6
11.1. Thus, a potent inflammatory stimulus leads to local T
cell expansion and Th1 differentiation even in response to
the systemic administration of normally tolerogenic antigen.
Discussion
The studies described in this paper were aimed at analyz-
ing the mechanisms of peripheral T cell tolerance in vivo.
Specifically, we examined the roles of a prototypic inflam-
matory cytokine, IL-12, and costimulatory molecules in
this process. The experimental models we have chosen in-
volve treating normal mice, or mice into which TCR
transgenic T cells are transferred, with high doses of antigen
without adjuvants. In the TCR transgenic system, it is pos-
sible to formally demonstrate that antigen-specific T cells
are not killed when they are exposed to tolerogenic anti-
gen, but are rendered functionally unresponsive, in that
they become incapable of producing IL-2, proliferating,
Figure 5. T cell anergy is prevented by a combination of IL-12 and anti-CTLA-4 antibody. BALB/c recipients of DO.11 T cells were immunized
with OVA323–339 peptide in IFA in the footpad on day 0, or tolerized with 300 mg of OVA323–339 peptide intraveneously on day 0, with or without daily
treatments (days 21, 0, 11) of 1 mg of IL-12 (tolerized 1 IL-12), 100 mg anti–CTLA-4 mAb (tolerized 1 anti–CTLA-4), or both IL-12 and anti–
CTLA-4 (tolerized 1 IL-12 and anti–CTLA-4). The submandibular, axillary, brachial, popliteal, and inguinal lymph nodes from all tolerized mice, and
popliteal and inguinal lymph nodes from immunized animals, were harvested 3 d later. Lymph node cells were restimulated in vitro with OVA323–339 peptide,
and assayed as in Fig. 2. Cytokine results are shown for cells restimulated with 1 mg/ml of OVA323–339 peptide; cells stimulated with no antigen showed
no detectable cytokine production. Tolerized mice given a control antibody (isotype-matched with anti–CTLA-4 mAb) behaved identically to mice
which were not given the antibody (reference 15 and data not shown). Results are pooled and averaged from two to four experiments with each treat-
ment group. The error bars represent standard deviations calculated.
Table 2. T Cell Expansion in Response to Antigen In Vivo
No. KJ-1261 cells (3 1024) per lymph node
Group Day 3
Naive 1.8 6 0.9
Immunized 29.0 6 3.6
Tolerized 12.2 6 2.4
1 IL-12 17.2 6 6.7
1 anti–CTLA-4 47.5 6 6.4
1 IL-12 and anti–CTLA-4 58.7 6 16.1
Peripheral lymph nodes (axillary, brachial, inguinal, and popliteal for na-
ive and tolerized mice, inguinal and popliteal only for immunized mice)
were harvested from adoptive transfer recipients which were treated as
described in the text. The percentage of KJ1-261 CD41 cells present was
determined by flow cytometry. To obtain the total numbers of KJ-1261
cells present per lymph node, the percent of KJ-1261 cells in lymph
nodes was multiplied by the total number of cells recovered in each group
and divided by the number of lymph nodes harvested. Every treatment
group consisted of two to three mice. The numbers shown are the aver-
ages of two to four experiments. All values are 3 1024, and the errors rep-
resent the standard deviations calculated.1126 Interleukin 12 and CTLA-4 in T Cell Anergy
and differentiating into Th1 effectors (Figs. 2 and 3, and
references 15 and 23). By these criteria, the form of toler-
ance induced by aqueous peptide antigen appears to be an
in vivo counterpart of the phenomenon of clonal anergy
first described in T cell clones (3, 4).
Our recent results have demonstrated that the role of
B7-mediated costimulation in T cell anergy in vivo is com-
plex, and somewhat unexpected. We have found that a B7
antagonist does not promote tolerance, as might have been
expected based on the results of in vitro studies (3, 4), but
rather it prevents the induction of anergy and keeps T cells
in a naive but functionally competent state. The induction
of tolerance depends on the engagement of B7 molecules,
presumably on APCs, by the CTLA-4 counter receptor on
antigen-responsive T cells (15). In striking contrast, T cell
priming, as measured by proliferation and differentiation
into effector cells, is dependent on B7 recognition by the
activating counter-receptor, CD28 (15, 25). These results
have led to the conclusion that a key determinant of T cell
activation versus tolerance is which receptor, CD28 or
CTLA-4, is used to engage B7 costimulators during T cell
antigen recognition (15). During these studies, we realized
that the block in Th1 differentiation associated with toler-
ance induction in vivo is unlikely to be solely due to
CTLA-4–B7 interactions, because giving anti–CTLA-4
antibody at the time of tolerance induction led to variable
amounts of IFN-g produced by antigen-specific T cells
(15). Moreover, in the earlier studies, tolerance was in-
duced by intraperitoneal injection of peptide in IFA, and in
subsequent experiments, when we induced tolerance with
aqueous peptide without any adjuvant, anti–CTLA-4 alone
was ineffective at allowing Th1 differentiation (Fig. 5).
This is not surprising, because the development of Th1 ef-
fector cells requires IL-12, which is produced by macro-
Figure 6. Local inflammation
prevents the induction of T cell
anergy in vivo. BALB/c recipi-
ents of DO.11 T cells were left
untreated (A); immunized with
OVA323–339 peptide in IFA in the
footpad on day 0 (B); or toler-
ized with 300 mg of OVA323–339
peptide intravenously on day 0
(C). Some tolerized mice also re-
ceived an injection of CFA in
the footpad (D and E). The sub-
mandibular, axillary, brachial,
popliteal, and inguinal lymph
nodes (only popliteal and in-
guinal lymph nodes in B) were
harvested 3 d later. From the
CFA-treated mice, popliteal, and
inguinal lymph node cells (D)
and the submandibular, axillary,
and brachial lymph node cells (E)
were harvested and assayed sepa-
rately. Lymph node cells were
restimulated in vitro with
OVA323–339 peptide and assayed
as in Fig. 2. Results are from one
representative experiment of
three. The error bars represent
standard deviations calculated
from duplicate wells.1127 Van Parijs et al.
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phages and dendritic cells usually in response to microbes
and other inflammatory stimuli (25). Tolerogenic antigens,
such as aqueous peptides administered intraveneously, are
unlikely to stimulate IL-12 production, since such antigens
do not contain macrophage-activating substances. We
therefore reasoned that to completely prevent T cell anergy
and allow effector cell development, it might be necessary
both to change the pattern of costimulator recognition and
to provide IL-12. Our experimental results support this no-
tion. A combination of anti–CTLA-4 antibody and recom-
binant IL-12 is sufficient to convert a tolerogenic form of
peptide antigen to a fully immunogenic form, whereas nei-
ther alone is sufficient (Fig. 5). These conclusions are most
convincingly demonstrated in the TCR transgenic adop-
tive transfer system, where the fates of antigen-specific
TCR transgenic T cells can be followed quantitatively.
However, it is likely that the same is true of tolerance in-
duced in normal T cell populations, since IL-12 promotes
Th1 differentiation but does not fully restore T cell expan-
sion in normal mice (Fig. 1). Furthermore, a strong adju-
vant, which induces local inflammation, has the same func-
tional effects on tolerance induction as the combination of
anti–CTLA-4 antibody and IL-12 (Fig. 6). Although this
does not prove that the effects of the adjuvant are due to a
change in costimulation and IL-12 production, the findings
are consistent with this idea. Importantly, IL-12 alone stim-
ulates production of the signature Th1 cytokine, IFN-g,
but does not prevent the proliferative block associated with
tolerance induction (Figs. 2 and 3). Therefore, the inflam-
matory cytokine by itself is insufficient for preventing T cell
tolerance.
The mechanisms by which anti–CTLA-4 antibody and
IL-12 cooperate to convert a tolerogenic stimulus to an
immunogenic one are not precisely defined. It is likely that
tolerogenic antigens administered without adjuvants induce
low levels of B7 costimulator expression on APCs. Such
low levels may preferentially engage the high-affinity re-
ceptor for B7 molecules, which is CTLA-4, triggering in-
hibitory biochemical signals which block IL-2 production
and T cell proliferation (26, 27). Antigen recognition by
T cells in the absence of IL-2 and proliferation is known to
lead to functional anergy (3, 5). Immunogenic forms of an-
tigen, such as peptides administered with strong adjuvants,
may induce higher levels and more prolonged expression of
B7 molecules, resulting in the engagement of CD28 and T
cell activation. Thus, changing B7 recognition from
CTLA-4 to CD28 may be sufficient to release the block in
IL-2 production and T cell proliferation. It appears unlikely
that this alone would induce T cell differentiation into ef-
fectors, because differentiation requires another signal(s),
which, for the Th1 pathway, is provided by IL-12. Thus,
adjuvants may trigger two distinct reactions that contribute
to preventing T cell tolerance and eliciting immune re-
sponses—they stimulate IL-12 production, and they alter
costimulator expression in a way that promotes engage-
ment by CD28.
The ability of IL-12 to function in preventing tolerance
induction is consistent with the finding that IL-12 is pro-
duced locally in lesions associated with autoimmune dis-
eases (28, 29). However, in these situations it is not possible
to establish if IL-12 production is a cause of the autoim-
mune reactions or the consequence of local T cell activa-
tion and IFN-g secretion. Moreover, it is not known if
blocking IL-12 will promote tolerance induction. Clearly,
this may not be an adequate treatment for inducing toler-
ance by itself, because if mice are immunized and treated
with IL-12 antagonists, the result is a defect in Th1 differ-
entiation, and not anergy (30). The same result is seen in
mice lacking the p40 chain of IL-12, and in mice in which
the major IL-12–triggered transcription factor, Stat4, is de-
leted (31–33). However, IL-12 antagonists administered
with agents that favor CTLA-4-B7 interactions, or with
forms of antigens that preferentially trigger such interac-
tions, may enhance the induction of anergy. It remains to
be determined if this will be useful for the thaerapeutic in-
duction of tolerance to prevent allograft rejection, or to
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